CR20230242A - Ácidos pirazol piperidin carboxílicos sustituidos - Google Patents

Ácidos pirazol piperidin carboxílicos sustituidos

Info

Publication number
CR20230242A
CR20230242A CR20230242A CR20230242A CR20230242A CR 20230242 A CR20230242 A CR 20230242A CR 20230242 A CR20230242 A CR 20230242A CR 20230242 A CR20230242 A CR 20230242A CR 20230242 A CR20230242 A CR 20230242A
Authority
CR
Costa Rica
Prior art keywords
diseases
carboxylic acids
piperidine carboxylic
substituted pyrazolo
pyrazolo piperidine
Prior art date
Application number
CR20230242A
Other languages
English (en)
Spanish (es)
Inventor
Andre Dieskau
Lisa Candish
Melissa Boultadakis-Arapinis
Ilka Mathar
Carsten Schmeck
Alexandros Vakalopoulos
Timo Stellfeld
Lucas Hudson Hofmeister
Marie-Pierre Collin-Kröpelin
Hernandez Nuria Ortega
Peter Sandner
Frank Wunder
Lisa Dietz
Robert Alan Webster
Thomas Mondritzki
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CR20230242A publication Critical patent/CR20230242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20230242A 2020-12-10 2021-12-09 Ácidos pirazol piperidin carboxílicos sustituidos CR20230242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
CR20230242A true CR20230242A (es) 2023-07-19

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230242A CR20230242A (es) 2020-12-10 2021-12-09 Ácidos pirazol piperidin carboxílicos sustituidos

Country Status (30)

Country Link
US (1) US20240051935A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552583A (cg-RX-API-DMAC7.html)
KR (1) KR20230118144A (cg-RX-API-DMAC7.html)
CN (1) CN116710439B (cg-RX-API-DMAC7.html)
AR (1) AR124297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021393988A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204495A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001632A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007335A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230242A (cg-RX-API-DMAC7.html)
DK (1) DK4259617T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000115A (cg-RX-API-DMAC7.html)
EC (1) ECSP23040828A (cg-RX-API-DMAC7.html)
ES (1) ES2997117T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259617T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247649B (cg-RX-API-DMAC7.html)
HR (1) HRP20241543T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069255T2 (cg-RX-API-DMAC7.html)
IL (1) IL303296A (cg-RX-API-DMAC7.html)
JO (1) JOP20230132A1 (cg-RX-API-DMAC7.html)
LT (1) LT4259617T (cg-RX-API-DMAC7.html)
MX (1) MX2023006903A (cg-RX-API-DMAC7.html)
PE (1) PE20231501A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259617T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259617T (cg-RX-API-DMAC7.html)
RS (1) RS66294B1 (cg-RX-API-DMAC7.html)
SA (1) SA523441083B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259617T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022122914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法
AU2024348074A1 (en) * 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
TW202535380A (zh) * 2024-01-30 2025-09-16 大陸商海思科醫藥集團股份有限公司 吡唑羧酸衍生物及其在醫藥上的應用
WO2026145681A1 (zh) * 2025-01-03 2026-07-09 上海齐鲁制药研究中心有限公司 杂环羧酸类衍生物、其制备方法及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101939053A (zh) * 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
MX338887B (es) * 2012-09-07 2016-05-04 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
US20170313665A1 (en) 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CA3204595A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
WO2022122917A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
US20240051935A1 (en) 2024-02-15
IL303296A (en) 2023-07-01
AU2021393988A9 (en) 2024-09-19
SA523441083B1 (ar) 2025-06-12
CN116710439A (zh) 2023-09-05
CO2023007335A2 (es) 2023-06-09
ECSP23040828A (es) 2023-07-31
AR124297A1 (es) 2023-03-15
FI4259617T3 (fi) 2024-11-27
JP2023552583A (ja) 2023-12-18
DOP2023000115A (es) 2023-07-16
LT4259617T (lt) 2024-12-10
EP4259617A1 (en) 2023-10-18
CA3204495A1 (en) 2022-06-16
GEAP202316287A (en) 2023-09-11
CL2023001632A1 (es) 2023-11-10
HRP20241543T1 (hr) 2025-01-03
ES2997117T3 (en) 2025-02-14
GEP20247649B (en) 2024-07-25
MX2023006903A (es) 2023-06-26
CN116710439B (zh) 2026-05-26
RS66294B1 (sr) 2025-01-31
KR20230118144A (ko) 2023-08-10
EP4259617B1 (en) 2024-10-23
TW202237589A (zh) 2022-10-01
PT4259617T (pt) 2024-12-05
WO2022122914A1 (en) 2022-06-16
SI4259617T1 (sl) 2025-02-28
PE20231501A1 (es) 2023-09-26
JOP20230132A1 (ar) 2023-06-08
PL4259617T3 (pl) 2025-03-17
HUE069255T2 (hu) 2025-02-28
DK4259617T3 (da) 2024-12-09
AU2021393988A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2025009051A (es) Acidos pirazolo piperidin carboxilicos sustituidos
MX2023006903A (es) Acidos pirazol piperidin carboxilicos sustituidos.
JP2019521976A5 (cg-RX-API-DMAC7.html)
Cartotto et al. Vasopressin for the septic burn patient
Akhtar et al. Cardiac tamponade on ECPELLA: a case report of a unique hemodynamic picture
Mahmood Serum potassium and calcium level in patients with post-myocardial infarction ventricular fibrillation
SAITOH et al. Effects of let ventricular systolic dysfunction and cardio-renal anemia syndrome on walking ability and Activities of Daily Living in patients with heart failure
Kraiem et al. P4718 Follow up in heart failure center versus routine practice: which positive impact we can have?
Shah et al. Isolated cor-triatriatum sinister presenting as new onset atrial-fibrillation in a 53-year-old female
Lang et al. Pulmonary Artery Endovascular Device to Improve Vascular Compliance in Pulmonary Hypertension
Haque et al. Clinical Response of Enhanced External Counter Pulsation (EECP) Among Bangladeshi Ischemic Heart Disease Patients
Towers et al. Complete heart block in young people
Hughes et al. Lungs
Pilato Pulmonary embolism: case report
Banerjee et al. Comparison of Echocardiographic Patterns between Mild to Moderate and Severe CKD with type 4 Cardio renal Syndrome Patients
Zeng et al. Sequential mechanical ventilation improves hemodynamics, cardiac function and neurohumoral status in elderly patients with acute left heart failure
Veerbhadran Intractable hyperkalaemia and cardiac arrest: case report
Balasanian et al. Massive pulmonary embolism and thrombophilia
Yoon Cisatracurium besilate
Nagata et al. A Case of Patient Suspected Familial Dilated Cardiomyopathy with Conduction Abnormality
Takada et al. Triglyceride Deposit Cardiomyovasculopathy with Severe Heart Failure
Yu et al. e0247 Prevalence of Metabolic syndrome and its effect on Carotid artery intima-media thickness in Xinjiang Kazak populations
CN106539801A (zh) 一种治疗心脏围手术期重度肺动脉高压的方法
Bhattacharya et al. C69 CONTROVERSY: ASSESSING AND TREATING THE FAILING RIGHT VENTRICLE: Right Ventricular Outflow Tract-Velocity Time Integral And Pulmonary Artery Systolic Pressure Ratio: A Novel Non-Invasive Marker Of Pulmonary Arterial Compliance In Pulmonary Arterial Hypertension Vs. Pulmonary Hypertension In Heart Failure With Preserved Ejection Fraction